LISA HEYBOER: Open Payments
NPI 1548283864 · GRAND RAPIDS, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$379 in 17 payments from 8 companies in 2025. Trend: 2023 $427 · 2024 $553 · 2025 $379
Food & beverage: $334Education: $46
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 2 | $75 |
| Genentech USA, Inc. | 3 | $68 |
| Pharming Healthcare, Inc. | 2 | $52 |
| GlaxoSmithKline, LLC. | 3 | $50 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $46 |
| Novartis Pharmaceuticals Corporation | 2 | $44 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $26 |
| AstraZeneca Pharmaceuticals LP | 1 | $19 |
Products named: DUPIXENT, Xolair, RUCONEST, NUCALA, NEFFY, BREZTRI, EOHILIA.
Industry payments across MI — which companies pay providers there.
